OHR Pharmaceutical Inc (NASDAQ:OHRP)

Data as of Oct 20
 +0.31 / +4.43%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Ohr Pharmaceutical, Inc. operates as a biotechnology company, which is focused on the development of its acquired compounds. Its products include OHR/AVR 118 for the treatment of Cancer Cachexia and EVIZON, which are used for the treatment of the wet form of age related macular degeneration. The company was founded in 2008 and is headquartered in New York, NY.

Contact Information

Ohr Pharmaceutical, Inc.
489 5th Avenue
New York New York 10017
P:(212) 682-8452
Investor Relations:



Mutual fund holders6.10%
Other institutional29.63%
Individual stakeholders13.99%

Top Executives

Irach B. TaraporewalaPresident, Chief Executive Officer & Director
Samuel I. BackenrothChief Financial Officer & VP-Business Development
Jason SlakterChief Medical Officer
Glenn StollerChief Scientific Officer
Peter K. KaiserSenior Vice President-Product Development

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.